DoNoHarm BC

📢💉🇨🇦Big update on Novavax / Nuvaxovid availability for Canada! Today, @SanofiCanada has announced, via @CNWNews, that they have completed the acquisition of Nuvaxovid market authorization from @Novavax and that Nuvaxovid will be available to Canadians in the fall. • Nuvaxovid will be made available in Canada by Sanofi for the fall 2026-2027 season • Provincial and territorial availability will be confirmed pending ongoing discussions and provincial assessments "With the launch of Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine, Sanofi is now able to offer Canadians greater choice when it comes to COVID-19 protection. The availability of Nuvaxovid means that every Canadian will have the opportunity to access their personal COVID-19 vaccine choice. Canadians have clearly expressed a need for a non-mRNA option when it comes to COVID-19 protection. With this transfer, Sanofi can now respond to that need." - Delphine Lansac, General Manager, Canada, Vaccines at Sanofi. Press release: newswire.ca/news-releases/… Sanofi appears to have created a webpage for the Canadian product here, which includes the current product monograph: sanofi.com/en/canada/your…

📢💉🇨🇦Update on Novavax / Nuvaxovid access in Canada: @SanofiCanada has confirmed that, at the current time, they DO plan to commercialize Nuvaxovid in Canada beginning with the 2026-2027 respiratory illness season, per a recent letter sent to @immunocompCA (immunocompromised.ca/wp-content/upl…) This correspondence is in reply to a June 2025 joint letter to Sanofi Canada by @CanCovSoc and @immunocompCA (covidsociety.ca/wp-content/upl…) Following all of the recent successes of @Novavax in the U.S. (another largely successful seasonal rollout (Sanofi’s first) and Pfizer’s recent deal to use Matrix-M adjuvant), we’ve been seeing more buzz than usual about expanding availability globally. It’s all great to see, but unfortunately, along with that (as is expected) always comes a lot of misinformation as well. To be clear, there has never been any issue with @GovCanHealth and the approval of Nuvaxovid. Nuvaxovid has remained approved since September 2024 (covid-vaccine.canada.ca/nuvaxovid-jn1/…), and, as Sanofi points out in the letter, they also just received a Notice of Compliance from Health Canada last July for the new prefilled syringe presentation with a 6-month shelf life (the same presentation and shelf life as the U.S. product). Nevertheless, contract issues have largely kept it from being available anyway for the past 2 seasons. Below, for anyone interested, is a detailed history of what happened between Novavax and the Canadian federal government a couple of years ago. In short: The original deal fell through because the Trudeau government had a demand for Novavax to produce doses domestically - something that never came to fruition. With new federal leadership, and with the product transitioning to Sanofi’s hands, the hope and expectation is to put that deal behind us and draft a new one that will make Nuvaxovid available for Canadians who demand access to the better COVID vaccine. Everyone wants it to happen, but we still need to continue to be vigilant and make sure that @sanofi @SanofiCanada @MarkJCarney @PSPC_SPAC @PHAC_GC @GovCanHealth @ONThealth get it done. Leave nothing up to interpretation, and continue to ensure that all stakeholders involved are well aware of the demand that exists for Nuvaxovid.

Advocacy opportunity 📣 Pre-register to present directly to BC gov about YOUR priorities for next year's provincial budget! Sign up by Friday April 10 at 2pm: consultation-portal.leg.bc.ca/consultations/… Presenting can be done virtually. They’ll follow up in May about whether you’ve been selected.